Table of Contents Author Guidelines Submit a Manuscript
Advances in Pharmacological Sciences
Volume 2014, Article ID 132034, 6 pages
http://dx.doi.org/10.1155/2014/132034
Research Article

Teratogenic Effects of Coadministration of Fluoxetine and Olanzapine on Rat Fetuses

1Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Pour Sina Street, Qods Street, Keshavarz Boulevard, Tehran 1417613151, Iran
2Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613146, Iran
3School of Medicine, Tehran University of Medical Sciences, Tehran 1417613110, Iran
4Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
5Department of Veterinary Sciences, University of Pisa, San Piero a Grado, Pisa 56122, Italy

Received 30 September 2013; Revised 25 November 2013; Accepted 16 December 2013; Published 16 January 2014

Academic Editor: Todd C. Skaar

Copyright © 2014 Azam Bakhtiarian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. Preskorn, R. Ross, and C. Stanga, “Selective serotonin reuptake inhibitors,” in Antidepressants: Past, Present and Future, vol. 157 of Handbook of Experimental Pharmacology, pp. 241–262, Springer, New York, NY, USA, 2004. View at Publisher · View at Google Scholar
  2. L. M. Arnold, “A case series of women with postpartum-onset obsessive-compulsive disorder,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 1, no. 4, pp. 103–108, 1999. View at Google Scholar · View at Scopus
  3. K. L. Wisner, K. S. Peindl, T. Gigliotti, and B. H. Hanusa, “Obsessions and compulsions in women with postpartum depression,” Journal of Clinical Psychiatry, vol. 60, no. 3, pp. 176–180, 1999. View at Google Scholar · View at Scopus
  4. K. E. Williams and L. M. Koran, “Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum,” Journal of Clinical Psychiatry, vol. 58, no. 7, pp. 330–334, 1997. View at Google Scholar · View at Scopus
  5. G. Maina, U. Albert, F. Bogetto, P. Vaschetto, and L. Ravizza, “Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery,” Psychiatry Research, vol. 89, no. 1, pp. 49–58, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. J. F. Leckman, W. K. Goodman, W. G. North et al., “Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder: comparison with Tourette's syndrome and healthy controls,” Archives of General Psychiatry, vol. 51, no. 10, pp. 782–792, 1994. View at Google Scholar · View at Scopus
  7. S. L. Dubovsky, “Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression,” Expert Opinion on Drug Metabolism and Toxicology, vol. 9, no. 2, pp. 207–214, 2013. View at Publisher · View at Google Scholar
  8. G. Z. Reus, H. M. Abelaira, F. R. Agostinho et al., “The administration of olanzapine and fluoxetine has synergistic effects on intracellular survival pathways in the rat brain,” Journal of Psychiatric Research, vol. 46, no. 8, pp. 1029–1035, 2012. View at Publisher · View at Google Scholar
  9. P. R. McElhatton, “The effects of benzodiazepine use during pregnancy and lactation,” Reproductive Toxicology, vol. 8, no. 6, pp. 461–475, 1994. View at Google Scholar · View at Scopus
  10. P. F. Brain, J. S. Ajarem, and V. V. Petkov, “The application of ethopharmacological techniques to behavioural teratology: preliminary investigations,” Acta Physiologica et Pharmacologica Bulgarica, vol. 12, no. 4, pp. 3–11, 1986. View at Google Scholar · View at Scopus
  11. R. C. Pohland, T. K. Byrd, M. Hamilton, and J. R. Koons, “Placental transfer and fetal distribution of fluoxetine in the rat,” Toxicology and Applied Pharmacology, vol. 98, no. 2, pp. 198–205, 1989. View at Google Scholar · View at Scopus
  12. C. V. Vorhees, K. D. Acuff-Smith, M. A. Schilling, J. E. Fisher, M. S. Moran, and J. Buelke-Sam, “A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats,” Fundamental and Applied Toxicology, vol. 23, no. 2, pp. 194–205, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. T. M. Cabrera-Vera, F. Garcia, W. Pinto, and G. Battaglia, “Effect of prenatal fluoxetine (prozac) exposure on brain serotonin neurons in prepubescent and adult male rat offspring,” Journal of Pharmacology and Experimental Therapeutics, vol. 280, no. 1, pp. 138–145, 1997. View at Google Scholar · View at Scopus
  14. R. A. Byrd and J. K. Markham, “Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits,” Fundamental and Applied Toxicology, vol. 22, no. 4, pp. 511–518, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Rosengarten and D. Quartermain, “Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats,” Pharmacology Biochemistry and Behavior, vol. 72, no. 3, pp. 575–579, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. X. M. Li, K. W. Perry, D. T. Wong, and F. P. Bymaster, “Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum,” Psychopharmacology, vol. 136, no. 2, pp. 153–161, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Aravagiri, Y. Teper, and S. R. Marder, “Pharmacokinetics and tissue distribution of olanzapine in rats,” Biopharmaceutics and Drug Disposition, vol. 20, no. 8, pp. 369–377, 1999. View at Publisher · View at Google Scholar
  18. D. J. Goldstein, K. L. Sundell, and L. A. Corbin, “Birth outcomes in pregnant women taking fluoxetine,” The New England Journal of Medicine, vol. 336, no. 12, pp. 872–873, 1997. View at Google Scholar · View at Scopus
  19. T. F. Oberlander, S. Misri, C. E. Fitzgerald, X. Kostaras, D. Rurak, and W. Riggs, “Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure,” Journal of Clinical Psychiatry, vol. 65, no. 2, pp. 230–237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Einarson, B. Fatoye, M. Sarkar et al., “Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study,” The American Journal of Psychiatry, vol. 158, no. 10, pp. 1728–1730, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Pastuszak, B. Schick-Boschetto, C. Zuber et al., “Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac),” The Journal of the American Medical Association, vol. 269, no. 17, pp. 2246–2248, 1993. View at Publisher · View at Google Scholar · View at Scopus
  22. E. L. Moses-Kolko, D. Bogen, J. Perel et al., “Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications,” The Journal of the American Medical Association, vol. 293, no. 19, pp. 2372–2383, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. R. C. Casper, B. E. Fleisher, J. C. Lee-Ancajas et al., “Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy,” Journal of Pediatrics, vol. 142, no. 4, pp. 402–408, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Cissoko, D. Swortfiguer, B. Giraudeau, A. Jonville-Béra, and E. Autret-Leca, “Neonatal outcome after exposure to selective serotonin reuptake inhibitors late in pregnancy,” Archives de Pediatrie, vol. 12, no. 7, pp. 1081–1084, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Gentile, “The safety of newer antidepressants in pregnancy and breastfeeding,” Drug Safety, vol. 28, no. 2, pp. 137–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. C. D. Chambers, K. A. Johnson, L. M. Dick, R. J. Felix, and K. L. Jones, “Birth outcomes in pregnant women taking fluoxetine,” The New England Journal of Medicine, vol. 335, no. 14, pp. 1010–1015, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. L. S. Cohen, V. L. Heller, J. W. Bailey, L. Grush, J. S. Ablon, and S. M. Bouffard, “Birth outcomes following prenatal exposure to fluoxetine,” Biological Psychiatry, vol. 48, no. 10, pp. 996–1000, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. A. M. Costei, E. Kozer, T. Ho, S. Ito, and G. Koren, “Perinatal outcome following third trimester exposure to paroxetine,” Archives of Pediatrics and Adolescent Medicine, vol. 156, no. 11, pp. 1129–1132, 2002. View at Google Scholar · View at Scopus
  29. D. J. Goldstein, “Effects of third trimester fluoxetine exposure on the newborn,” Journal of Clinical Psychopharmacology, vol. 15, no. 6, pp. 417–420, 1995. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Dodd and M. Berk, “Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility,” Expert Review of Neurotherapeutics, vol. 8, no. 9, pp. 1299–1306, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. W. J. Burke, S. E. Hendricks, D. McArthur-Miller et al., “Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial,” Journal of Clinical Psychopharmacology, vol. 20, no. 4, pp. 423–427, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Pérez, D. Puigdemont, I. Gilaberte, E. Alvarez, and F. Artigas, “Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors,” Journal of Clinical Psychopharmacology, vol. 21, no. 1, pp. 36–45, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. D. J. Brunswick, J. D. Amsterdam, J. Fawcett et al., “Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment,” Journal of Affective Disorders, vol. 68, no. 2-3, pp. 243–249, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. H. K. Crewe, M. S. Lennard, G. T. Tucker, F. R. Woods, and R. E. Haddock, “The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes,” The British Journal of Clinical Pharmacology, vol. 34, no. 3, pp. 262–265, 1992. View at Google Scholar · View at Scopus
  35. J. A. Carrillo, A. G. Herráiz, S. I. Ramos, G. Gervasini, S. Vizcaíno, and J. Benítez, “Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine,” Journal of Clinical Psychopharmacology, vol. 23, no. 2, pp. 119–127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. N. Takzare, V. Nikoui, S. Ostadhadi, S. M. A. Nabavi, and A. Bakhtiarian, “Teratogenic effects of caffeine and clomipramine on rat fetus,” Tehran University Medical Journal, vol. 70, no. 6, pp. 335–339, 2012. View at Google Scholar
  37. J. A. Carrillo and J. Benitez, “Clinically significant pharmacokinetic interactions between dietary caffeine and medications,” Clinical Pharmacokinetics, vol. 39, no. 2, pp. 127–153, 2000. View at Google Scholar · View at Scopus
  38. N. Takzare, A. Bakhtiarian, E. Saeedi, and V. Nekoui, “The teratogenic effects of alprazolam intake on rat fetus,” Tehran University Medical Journal, vol. 68, no. 10, pp. 578–582, 2011. View at Google Scholar · View at Scopus
  39. S. W. Wen, Q. Yang, P. Garner et al., “Selective serotonin reuptake inhibitors and adverse pregnancy outcomes,” The American Journal of Obstetrics and Gynecology, vol. 194, no. 4, pp. 961–966, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Malek-Ahmadi, “Olanzapine in pregnancy,” Annals of Pharmacotherapy, vol. 35, no. 10, pp. 1294–1295, 2001. View at Google Scholar · View at Scopus